Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | GRN | P28799 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30494127 | 1.00 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| Pyrrole SCHEMBL28577580 | 0.93 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL10356523 | 0.88 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28286266 | 0.83 | RAB9A (0.51) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21865083 | 0.82 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4651782 | 0.82 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL4277314 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6616258 | 0.81 | KMT2A (0.60) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1681081 | 0.81 | CYP1A2 (0.58) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1209894 | 0.81 | GABRA2 (0.52) | ALDH1A1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0070518-A2 | Imidazoquinoxaline compounds | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1983-01-26 | — | — | EP | claimed |
| EP-3183250-B1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | CLAP CO LTD (KR) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023138599-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-116462662-A | Aromatic ring Nav1.8 inhibitor and application thereof | 成都康弘药业集团股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-3183757-B1 | ORGANIC SEMICONDUCTOR COMPOSITION COMPRISING LIQUID MEDIUM | CLAP CO LTD (KR) | 2022-05-04 | — | — | EP | disclosed |
| US-10454037-B2 | Organic semiconductor composition comprising a liquid medium | BASF SE (DE) | 2019-10-22 | — | — | US | disclosed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | disclosed |
| US-10043978-B2 | Organic semiconductor formulations | FLEXTERRA, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | disclosed |
| CN-1036003-C | A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1997-10-01 | — | — | CN | disclosed |
| EP-0724908-A1 | Noble metal raney catalysts and preparation of hydrogenated compounds using such catalysts | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1996-08-07 | — | — | EP | disclosed |
| CN-1106005-A | A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-08-02 | — | — | CN | disclosed |
| CN-1106004-A | A process for preparing (1H-azol-1-ylmethyl) substituted quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-08-02 | — | — | CN | disclosed |
| CN-1042912-A | (1H-oxazol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1990-06-13 | — | — | CN | disclosed |
| EP-0070518-A2 | Imidazoquinoxaline compounds | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10454037-B2 | Organic semiconductor composition comprising a liquid medium | CRY1, NEFM, OR10J3 | ALDH1A1 4298/4885MEN1 2472/4885KMT2A 4158/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | ALDH1A1 4757/4885MEN1 722/4885KMT2A 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.